Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test may spot liver cancer earlier in hepatitis c patients

NCT ID NCT07404566

Diagnosis Sponsor: Benha University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether measuring tiny molecules called microRNAs in the blood can help diagnose liver cancer (hepatocellular carcinoma) in people with hepatitis C. Researchers tested blood samples from 84 participants, including healthy people and those with hepatitis C, with or without liver cancer. They measured five specific microRNAs to see if they could accurately tell apart liver cancer from other liver conditions. The goal is to develop a more reliable screening tool than current blood tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PCR measurement of microRNA levels (MiR-21, 1246, 205, 29a-3p, 497) in blood
What this could lead to
If successful, this could lead to a simple blood test that detects liver cancer earlier and more accurately in people with hepatitis C.
What could go wrong
This is a small, completed study with 84 participants, so results may not apply to larger or different groups. The test is still experimental and not yet ready for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

84 people

The number who actually took part.

Started

Aug 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals attending outpatient clinics for new or chronic HCV follow-up, and healthy volunteers from blood banks, primarily located in Egypt.

Ages

19 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed HCV infection. * Chronic uncomplicated HCV infection. * HCV complicated with liver cirrhosis. * HCV complicated with HCC on top of cirrhosis. * Willingness to participate and sign written informed consent. Exclusion Criteria: * Advanced stage of hepatic cirrhosis with portal hypertension or hepatorenal failure. * Hepatic malignancies other than HCC. * Bilharzial pre-portal fibrosis. * Alcoholic fatty liver disease * hepatosteatosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis C virus infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver hepatitis C virus infection hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Alexandria Faculty of medicine

    Alexandria, El Alexandria, 21512, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.